These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

797 related articles for article (PubMed ID: 23702337)

  • 21. Impact of continued mailed fecal tests in the patient-centered medical home: Year 3 of the Systems of Support to Increase Colon Cancer Screening and Follow-Up randomized trial.
    Green BB; Anderson ML; Chubak J; Fuller S; Meenan RT; Vernon SW
    Cancer; 2016 Jan; 122(2):312-21. PubMed ID: 26488332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes from the CDC's Colorectal Cancer Screening Demonstration Program.
    Seeff LC; Royalty J; Helsel WE; Kammerer WG; Boehm JE; Dwyer DM; Howe WR; Joseph D; Lane DS; Laughlin M; Leypoldt M; Marroulis SC; Mattingly CA; Nadel MR; Phillips-Angeles E; Rockwell TJ; Ryerson AB; Tangka FK
    Cancer; 2013 Aug; 119 Suppl 15():2820-33. PubMed ID: 23868476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
    Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
    Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Faecal occult blood testing (FOBT)-based colorectal cancer screening trends and predictors of non-use: findings from the South Australian setting and implications for increasing FOBT uptake.
    Todorov K; Wilson C; Sharplin G; Corsini N
    Aust Health Rev; 2018 Feb; 42(1):45-52. PubMed ID: 28248632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Equity of colorectal cancer screening: which groups have inequitable participation and what can we do about it?
    Ward PR; Javanparast S; Wilson C
    Aust J Prim Health; 2011; 17(4):334-46. PubMed ID: 22112702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy?
    van Dam L; Korfage IJ; Kuipers EJ; Hol L; van Roon AH; Reijerink JC; van Ballegooijen M; van Leerdam ME
    Eur J Cancer; 2013 Jul; 49(10):2321-30. PubMed ID: 23571149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effectiveness of the FLU-FOBT program in primary care a randomized trial.
    Potter MB; Walsh JM; Yu TM; Gildengorin G; Green LW; McPhee SJ
    Am J Prev Med; 2011 Jul; 41(1):9-16. PubMed ID: 21665058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fecal occult blood testing instructions and impact on patient adherence.
    Bapuji SB; Lobchuk MM; McClement SE; Sisler JJ; Katz A; Martens P
    Cancer Epidemiol; 2012 Aug; 36(4):e258-64. PubMed ID: 22504053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of follow-up colonoscopy after positive FOBT in an organized colorectal cancer screening program is associated with modifiable health care practices.
    Correia A; Rabeneck L; Baxter NN; Paszat LF; Sutradhar R; Yun L; Tinmouth J
    Prev Med; 2015 Jul; 76():115-22. PubMed ID: 25895843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up.
    Scholefield JH; Moss SM; Mangham CM; Whynes DK; Hardcastle JD
    Gut; 2012 Jul; 61(7):1036-40. PubMed ID: 22052062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
    Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
    J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colonoscopy and fecal occult blood test use in Germany: results from a large insurance-based cohort.
    Stock C; Ihle P; Schubert I; Brenner H
    Endoscopy; 2011 Sep; 43(9):771-81. PubMed ID: 21830189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in colorectal cancer screening disparities in people aged 50-64 years, 2000-2005.
    Trivers KF; Shaw KM; Sabatino SA; Shapiro JA; Coates RJ
    Am J Prev Med; 2008 Sep; 35(3):185-93. PubMed ID: 18617355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Features of colorectal cancer with fecal-occult-blood tests--comparison with colorectal cancer with no screening].
    Takemasa I; Kikkawa N; Yasui M; Nishisho I; Fujitani K; Mishima H; Hasuike Y; Kobayashi K
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1514-8. PubMed ID: 9725042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of National Colorectal Cancer Screening Program in Croatia (2007-2011).
    Katičić M; Antoljak N; Kujundžić M; Stamenić V; Skoko Poljak D; Kramarić D; Stimac D; Strnad Pešikan M; Samija M; Ebling Z
    World J Gastroenterol; 2012 Aug; 18(32):4300-7. PubMed ID: 22969192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temporal trends in new diagnoses of colorectal cancer with obstruction, perforation, or emergency admission in Ontario: 1993-2001.
    Rabeneck L; Paszat LF; Rothwell DM; He J
    Am J Gastroenterol; 2005 Mar; 100(3):672-6. PubMed ID: 15743367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Equity and practice issues in colorectal cancer screening: Mixed-methods study.
    Buchman S; Rozmovits L; Glazier RH
    Can Fam Physician; 2016 Apr; 62(4):e186-93. PubMed ID: 27618142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lesions detected in a colorectal cancer screening program in the Basque Country: first round (2009-2011)].
    Portillo I; Idígoras I; Ojembarrena E; Arana E; Luis Hurtado J; Basurko R; Tapia M; Luz Peña M
    Gastroenterol Hepatol; 2013 May; 36(5):301-8. PubMed ID: 23618538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Would general practitioners support a population-based colorectal cancer screening programme of faecal-occult blood testing?
    Tong S; Hughes K; Oldenburg B; Del Mar C
    Intern Med J; 2004; 34(9-10):532-8. PubMed ID: 15482265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.